Literature DB >> 17337505

Sulfonylurea treatment in young children with neonatal diabetes: dealing with hyperglycemia, hypoglycemia, and sick days.

Ethel Codner, Sarah E Flanagan, Francisca Ugarte, Hernán García, Teresa Vidal, Sian Ellard, Andrew T Hattersley.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17337505     DOI： 10.2337/dc06-2134

Source DB:  PubMed          Journal:  Diabetes Care        ISSN： 0149-5992            Impact factor:   19.112


× No keyword cloud information.
  12 in total

1.  Analysis of the characteristics and management of critical values in a newborn tertiary center in China.

Authors:  Zheng-Li Wang; Li-Zhong Du; Yi-Yu Chen; Lu-Quan Li; Qi Lu; Ying Liu; Lu-Ying Cao; Yu He; Jia-Lin Yu
Journal:  World J Pediatr       Date:  2016-09-15       Impact factor: 2.764

Review 2.  Current understanding of K ATP channels in neonatal diseases: focus on insulin secretion disorders.

Authors:  Yi Quan; Andrew Barszczyk; Zhong-ping Feng; Hong-shuo Sun
Journal:  Acta Pharmacol Sin       Date:  2011-05-23       Impact factor: 6.150

3.  Sulfonylurea treatment before genetic testing in neonatal diabetes: pros and cons.

Authors:  David Carmody; Charles D Bell; Jessica L Hwang; Jazzmyne T Dickens; Daniela I Sima; Dania L Felipe; Carrie A Zimmer; Ajuah O Davis; Kateryna Kotlyarevska; Rochelle N Naylor; Louis H Philipson; Siri Atma W Greeley
Journal:  J Clin Endocrinol Metab       Date:  2014-12       Impact factor: 5.958

4.  Permanent neonatal diabetes caused by dominant, recessive, or compound heterozygous SUR1 mutations with opposite functional effects.

Authors:  Sian Ellard; Sarah E Flanagan; Christophe A Girard; Ann-Marie Patch; Lorna W Harries; Andrew Parrish; Emma L Edghill; Deborah J G Mackay; Peter Proks; Kenju Shimomura; Holger Haberland; Dennis J Carson; Julian P H Shield; Andrew T Hattersley; Frances M Ashcroft
Journal:  Am J Hum Genet       Date:  2007-06-29       Impact factor: 11.025

5.  Transition from insulin to sulfonylurea in a child with diabetes due to a mutation in KCNJ11 encoding Kir6.2--initial and long-term response to sulfonylurea therapy.

Authors:  Verena M Wagner; Britta Kremke; Olaf Hiort; Sarah E Flanagan; Ewan R Pearson
Journal:  Eur J Pediatr       Date:  2008-06-12       Impact factor: 3.183

Review 6.  Neonatal diabetes mellitus.

Authors:  Lydia Aguilar-Bryan; Joseph Bryan
Journal:  Endocr Rev       Date:  2008-04-24       Impact factor: 19.871

7.  Long-term Follow-up of Glycemic and Neurological Outcomes in an International Series of Patients With Sulfonylurea-Treated ABCC8 Permanent Neonatal Diabetes.

Authors:  Pamela Bowman; Frances Mathews; Fabrizio Barbetti; Maggie H Shepherd; Janine Sanchez; Barbara Piccini; Jacques Beltrand; Lisa R Letourneau-Freiberg; Michel Polak; Siri Atma W Greeley; Eamon Rawlins; Tarig Babiker; Nicholas J Thomas; Elisa De Franco; Sian Ellard; Sarah E Flanagan; Andrew T Hattersley
Journal:  Diabetes Care       Date:  2020-11-12       Impact factor: 19.112

8.  Neonatal diabetes caused by activating mutations in the sulphonylurea receptor.

Authors:  Peter Proks
Journal:  Diabetes Metab J       Date:  2013-06       Impact factor: 5.376

9.  Molecular mechanism of sulphonylurea block of K(ATP) channels carrying mutations that impair ATP inhibition and cause neonatal diabetes.

Authors:  Peter Proks; Heidi de Wet; Frances M Ashcroft
Journal:  Diabetes       Date:  2013-07-08       Impact factor: 9.461

10.  Decreasing cx36 gap junction coupling compensates for overactive KATP channels to restore insulin secretion and prevent hyperglycemia in a mouse model of neonatal diabetes.

Authors:  Linda M Nguyen; Marina Pozzoli; Thomas H Hraha; Richard K P Benninger
Journal:  Diabetes       Date:  2014-01-23       Impact factor: 9.461
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.